title: The use of CA-IX as a diagnostic method for oral leukoplakia.
abstract: The presence and degree of dysplasia are important diagnostic and prognostic criteria for oral leukoplakia, but evaluation of dysplasia is difficult and subjective. Carbonic anhydrase-IX (CA-IX) is expressed primarily in tumor cells and is considered a specific hypoxia marker. We investigated the role of CA-IX in oral leukoplakia. We investigated 30 specimens of oral leukoplakia and 35 dysplasia specimens adjacent to the tumor margin. We analyzed clinical variables including age, sex, degree of dysplasia, and smoking, clinical appearance of leukoplakia, number of lesions, location, size, clinical monitoring, malignant transformation and recurrence. For the immunohistochemical study, we used a noncommercial monoclonal antibody against human CA-IX MAb M75. We found greater CA-IX positivity in nonsmokers, erythroplakia and mottled leukoplakia, those located on the tongue, patients with multiple lesions, 2-4 cm leukoplakias and in recurrent cases, although differences were not statistically significant. All lesions in all samples without dysplasia were negative for CA-IX; however, for all other categories of dysplasia, the percentages of positivity and negativity varied. Regarding the diagnostic index values, we found a sensitivity of 32%, specificity of 100%, a positive predictive value of 100% and a negative predictive value of 13%. Leukoplakias appear mainly in females and potentially are malignant; more than 90% have some degree of dysplasia, and therefore require close clinical and histopathological monitoring. The CA-IX immunohistochemical marker may be useful for screening samples without dysplasia owing to its high specificity.
authors.affiliation: Oral Medicine, Oral Surgery and Implantology Unit, Faculty of Medicine and Dentistry, Institute of Sanitary Research of Santiago , Entrerrios s/n, Santiago de Compostela C.P. 15782 , Spain.
authors.forename: M
authors.initials: M
authors.lastname: Pérez-Sayáns
authors.forename: J M
authors.initials: JM
authors.lastname: Suárez-Peñaranda
authors.forename: M
authors.initials: M
authors.lastname: Torres-López
authors.forename: C T
authors.initials: CT
authors.lastname: Supuran
authors.forename: P
authors.initials: P
authors.lastname: Gándara-Vila
authors.forename: P
authors.initials: P
authors.lastname: Gayoso-Diz
authors.forename: F
authors.initials: F
authors.lastname: Barros-Angueira
authors.forename: M
authors.initials: M
authors.lastname: Gallas-Torreira
authors.forename: A
authors.initials: A
authors.lastname: García-García
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000032:analysis*; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D007972:Leukoplakia, Oral / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000175:diagnosis* / Q000473:pathology; D011230:Precancerous Conditions / Q000473:pathology; D011379:Prognosis
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases
keywords: CA-IX; dysplasia; oral leukoplakia